BlossomHill Therapeutics, Inc. — insider transactions
43 transactions on record · CIK 1839970
Aggregates
computed from the filings belowPurchases, 12m
7
count of open-market buys
Sales, 12m
36
count of open-market sales
Buy / sell ratio, 12m
0.19
purchases per sale
Distinct insiders, 12m
10
Bought, 3m
$25.2M
Sold, 3m
$0
Median disclosure lag
0.0 d
trade date to filing date
Largest single trade, 24m
$10M
2026-08-10
Director share, 12m
67.4%
of transactions where role is stated
Current run
2 sells
consecutive same-direction transactions
Net 3m flow
$25.2M
purchases minus sales
Total on record
43
Transactions
43 most recent shown| Disclosed | Traded | Lag, d | Insider | Role | Transaction | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | 2026-08-10 | 2 | OrbiMed Capital GP VIII LLC | Director | Conversion of derivative | 1,039,996 | — | — | filing |
| 2026-08-12 | 2026-08-10 | 2 | OrbiMed Capital GP VIII LLC | Director | Conversion of derivative | 1,039,996 | $0.00 | — | filing |
| 2026-08-12 | 2026-08-10 | 2 | GORDON CARL L | Director | Open market purchase | 625,000 | $16.00 | $10M | filing |
| 2026-08-12 | 2026-08-10 | 2 | OrbiMed Capital GP VIII LLC | Director | Open market purchase | 625,000 | $16.00 | $10M | filing |
| 2026-08-12 | 2026-08-10 | 2 | GORDON CARL L | Director | Conversion of derivative | 1,049,283 | — | — | filing |
| 2026-08-12 | 2026-08-10 | 2 | GORDON CARL L | Director | Conversion of derivative | 1,049,283 | $0.00 | — | filing |
| 2026-08-12 | 2026-08-10 | 2 | OrbiMed Capital GP VIII LLC | Director | Conversion of derivative | 1,049,283 | — | — | filing |
| 2026-08-12 | 2026-08-10 | 2 | OrbiMed Capital GP VIII LLC | Director | Conversion of derivative | 1,049,283 | $0.00 | — | filing |
| 2026-08-12 | 2026-08-10 | 2 | GORDON CARL L | Director | Conversion of derivative | 1,039,996 | — | — | filing |
| 2026-08-12 | 2026-08-10 | 2 | GORDON CARL L | Director | Conversion of derivative | 1,039,996 | $0.00 | — | filing |
| 2026-08-10 | 2026-08-06 | 4 | Agrawal Sundeep | Director | Grant or award | 23,904 | $0.00 | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Agrawal Sundeep | Director | Conversion of derivative | 578,524 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Agrawal Sundeep | Director | Conversion of derivative | 578,524 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cormorant Private Healthcare Fund VI, LP | 10% Owner | Conversion of derivative | 1,599,993 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cormorant Private Healthcare Fund VI, LP | 10% Owner | Conversion of derivative | 1,701,541 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cormorant Private Healthcare Fund VI, LP | 10% Owner | Conversion of derivative | 1,599,993 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Schmid John P. | Director | Open market purchase | 6,000 | $16.00 | $96K | filing |
| 2026-08-10 | 2026-08-10 | 0 | Li Yishan | Director, Executive Chairman, 10% Owner | Conversion of derivative | 1,600,682 | — | — | filing |
| 2026-08-10 | 2026-08-06 | 4 | Li Yishan | Director, Executive Chairman, 10% Owner | Grant or award | 112,701 | $0.00 | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Li Yishan | Director, Executive Chairman, 10% Owner | Conversion of derivative | 124,779 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cui Jingrong Jean | Director, President and CEO, 10% Owner | Conversion of derivative | 124,779 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cui Jingrong Jean | Director, President and CEO, 10% Owner | Conversion of derivative | 113,435 | — | — | filing |
| 2026-08-10 | 2026-08-07 | 3 | Liptak Vincent Paul | General Counsel | Open market purchase | 2,500 | $15.80 | $39.5K | filing |
| 2026-08-10 | 2026-08-06 | 4 | Liptak Vincent Paul | General Counsel | Grant or award | 46,561 | $0.00 | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cormorant Private Healthcare Fund VI, LP | 10% Owner | Open market purchase | 312,500 | $16.00 | $5M | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cormorant Private Healthcare Fund VI, LP | 10% Owner | Conversion of derivative | 1,701,541 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Keyes Jason A | Chief Financial Officer | Open market purchase | 700 | $16.00 | $11.2K | filing |
| 2026-08-10 | 2026-08-10 | 0 | Li Yishan | Director, Executive Chairman, 10% Owner | Conversion of derivative | 113,435 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Li Yishan | Director, Executive Chairman, 10% Owner | Conversion of derivative | 1,600,682 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cui Jingrong Jean | Director, President and CEO, 10% Owner | Conversion of derivative | 1,600,682 | — | — | filing |
| 2026-08-10 | 2026-08-06 | 4 | Cui Jingrong Jean | Director, President and CEO, 10% Owner | Grant or award | 676,205 | $0.00 | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cui Jingrong Jean | Director, President and CEO, 10% Owner | Conversion of derivative | 124,779 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Liptak Vincent Paul | General Counsel | Open market purchase | 2,200 | $16.00 | $35.2K | filing |
| 2026-08-10 | 2026-08-10 | 0 | Liptak Vincent Paul | General Counsel | Conversion of derivative | 22,687 | — | — | filing |
| 2026-08-10 | 2026-08-06 | 4 | Cormorant Private Healthcare Fund VI, LP | 10% Owner | Grant or award | 23,904 | $0.00 | — | filing |
| 2026-08-10 | 2026-08-06 | 4 | GORDON CARL L | Director | Grant or award | 23,904 | $0.00 | — | filing |
| 2026-08-10 | 2026-08-06 | 4 | Keyes Jason A | Chief Financial Officer | Grant or award | 56,746 | $0.00 | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Li Yishan | Director, Executive Chairman, 10% Owner | Conversion of derivative | 124,779 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Li Yishan | Director, Executive Chairman, 10% Owner | Conversion of derivative | 113,435 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cui Jingrong Jean | Director, President and CEO, 10% Owner | Conversion of derivative | 113,435 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Cui Jingrong Jean | Director, President and CEO, 10% Owner | Conversion of derivative | 1,600,682 | — | — | filing |
| 2026-08-10 | 2026-08-10 | 0 | Liptak Vincent Paul | General Counsel | Conversion of derivative | 22,687 | — | — | filing |
| 2026-08-10 | 2026-08-06 | 4 | Oxnard Geoffrey Raymond | Chief Medical Officer | Grant or award | 61,783 | $0.00 | — | filing |